New stock news | New Hehua Port's IPO prospectus invalid

Sichuan Xinhehua Traditional Chinese Medicine Slices Co., Ltd. (referred to as Xinhehua) submitted its Hong Kong IPO prospectus on October 17, 2025, which expired after 6 months on April 17, 2026. GF SEC (Hong Kong) and Agricultural Bank International were the joint sponsors when the document was submitted. The prospectus shows that Xinhehua is one of the largest suppliers of traditional Chinese medicine slices in China. According to data from Frost & Sullivan, based on the revenue of traditional Chinese medicine slices in 2024, the company ranks second in China, holding a 0.4% market share in a competitive market environment, while the top five market participants collectively hold a 2.7% market share. The company is also the fastest-growing among the top five market participants, with a compound annual growth rate of 27% from 2022 to 2024. Xinhehua adopts a dual-pillar strategy, balancing its leading position in the core traditional Chinese medicine market with rapid response solutions for modern consumers. On the one hand, the company mainly serves corporate clients through offline channels, including over 1,000 hospitals and medical institutions, large chain pharmacies, as well as small pharmacies, clinics, and operators. On the other hand, by providing consumer-centric health products, the company taps into the growth potential of the retail market. Additionally, the company is seizing global opportunities through the export of herbal products and the establishment of localized operations in high-potential international markets.